RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced that Timothy Albury has been named the company’s Chief Financial Officer (CFO). In this role, Mr. Albury will be a key member of the executive management team that is responsible for leading the overall strategy and direction of the company, while also maintaining fiscal oversight of the company’s management and operations, including facilities and IT.
Mr. Albury joins Liquidia from Osmotica Pharmaceutical Corp., a global pharmaceutical company specializing in drug delivery technologies and neurology-based therapies. As CFO at Osmotica, Mr. Albury helped the company to develop and commercialize new drug candidates in the U.S., Europe and around the world, achieving annual product sales in excess of $400 million. During his tenure, he led a global financial restructuring, the creation and execution of the strategic plan and co-led merger & acquisition (M&A) efforts, as well as international collaboration strategy and execution.
“We are very pleased to welcome someone with Tim’s background and experience to the Liquidia team. Tim’s financial expertise and his demonstrated ability to successfully grow companies will make him a key contributor as Liquidia accelerates its product development capabilities and continues to leverage the PRINT platform to advance more products across different applications,” said Neal Fowler, Chief Executive Officer at Liquidia.
Throughout his 24-year career in the biotechnology and biopharmaceutical industry as well as in public accounting, Mr. Albury has played a key role as a financial strategist for initial public offerings (IPOs), external financing, licensing transactions and partnerships. He has been the CFO of several early stage companies, many of which had alliances and joint ventures with major pharmaceutical companies. Tim has been integrally involved in developing company strategy and organizing teams and resources to achieve business objectives.
Mr. Albury has a BS in Accounting, an MS in Professional Accountancy, and is a CPA in North Carolina and Florida.
ABOUT LIQUIDIA TECHNOLOGIES
Liquidia Technologies, founded in 2004, is a privately held biotechnology company located in Research Triangle Park, North Carolina. By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has become the only company in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape or composition using a unique particle engineering and manufacturing technology known as the PRINT® (Particle Replication In Non-Wetting Templates) platform. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have otherwise been out of reach for the life sciences industry. Liquidia and its partners are currently exploring the application of this novel technology to develop products in several high growth areas such as vaccines, pulmonology, oncology and ophthalmology. In addition to the development of its own products, Liquidia licenses the PRINT particle technology and its cGMP manufacturing capabilities to support proprietary programs advanced by collaborators. For more information, please go to www.liquidia.com.
